Literature DB >> 27011292

Intrathecal amantadine for prolonged spinal blockade of sensory and motor functions in rats.

Jann-Inn Tzeng1, Chung-Dann Kan2, Jieh-Neng Wang3, Jhi-Joung Wang4, Heng-Teng Lin5,6, Ching-Hsia Hung7,8.   

Abstract

We aimed to compare the hypothesized local anesthetic action of amantadine (1-adamantanamine) with that of the known local anesthetic mepivacaine. Motor, proprioceptive, and nociceptive functions were evaluated in rats after intrathecal administration. Amantadine elicited spinal anesthesia in a dose-related fashion and produced a better sensory-selective action over motor blockade (P < 0.01). On the 50% effective dose (ED50 ) basis, the rank of potency on spinal motor, proprioceptive, and nociceptive block was mepivacaine > amantadine (P < 0.01 for the differences). Amantadine (63.5 μmol/kg) and mepivacaine (7.1 μmol/kg) produced complete spinal block of motor function, proprioception, and nociception. On an equipotent basis (ED25 , ED50 , and ED75 ), the duration of amantadine was longer (P < 0.01) than that of mepivacaine on spinal motor, proprioceptive, and nociceptive block. Our preclinical data demonstrated that amantadine was less potent than mepivacaine at producing spinal anesthesia. The spinal block duration produced by amantadine was greater than that produced by mepivacaine. Both amantadine and mepivacaine produced a markedly nociceptive-specific blockade.
© 2016 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  amantadine; intrathecal injection; mepivacaine; spinal anesthesia

Mesh:

Substances:

Year:  2016        PMID: 27011292     DOI: 10.1111/fcp.12200

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  1 in total

1.  Intrathecal pramipexole and selegiline for sensory and motor block in rats.

Authors:  Chun-Chang Yeh; An-Kuo Chou; Yu-Wen Chen; Ching-Hsia Hung; Chong-Chi Chiu; Jhi-Joung Wang; Guan-Cheng Zhu
Journal:  Pharmacol Rep       Date:  2022-05-13       Impact factor: 3.024

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.